drugset / Trial / NCT05860114
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
NaSingle-groupOpen-labelTreatment
Summary
Primary objective: To evaluate the plasma and urine PK of Givinostat following multiple oral doses of Givinostat. Secondary objective: To assess the safety and tolerability multiple oral doses of Givinostat.
Timeline
- Start
- 2022-03-21
- Primary completion
- 2022-05-08
- Completion
- 2022-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Givinostat | Small molecule | 50 mg | Oral |
Indications
No indication recorded.